What Lucane Pharma does

Lucane Pharma is a Paris-headquartered pharmaceutical company founded in 2009 that develops and commercializes medicinal products for rare disorders. It operates as a wholly-owned subsidiary of Eurocept Pharmaceuticals Holding, a Dutch private holding founded in 2001. The company is led by CEO Thomas Calis and operates alongside sister entities Lucane SAS, Eurocept B.V., and Eurocept Xytron Medical B.V.

Lucane's commercial portfolio comprises five reformulated niche molecules: Xaluprine (mercaptopurine oral suspension for acute lymphocytic leukemia), Ucedane (carglumic acid for urea cycle disorders), Pheburane (sodium phenylbutyrate for urea cycle disorders, in granules and oral solution), Granupas (para-aminosalicylic acid for multidrug-resistant tuberculosis), and Amsalyo (amsacrine). Four EMA marketing authorizations have been secured (2013, 2014, 2017, 2023), plus approvals in Turkey and Canada, and the company is developing nine additional products targeting very rare disorders. The technical differentiator is reformulation and age-appropriate presentation design — notably for neonatal and pediatric dosing — rather than novel molecule discovery.

The business model is direct pharmaceutical commercialization in six European markets (France, Turkey, Spain, Italy, UK, Benelux) combined with distributor partnerships for global reach. Lucane deploys a specialized scientific sales team that engages the small number of physicians treating each rare condition, and distributes directly to hospitals and retail pharmacies to guarantee supply for patient populations as small as one or two per country. Pricing is negotiated with national health authorities rather than publicly disclosed. The company is actively seeking additional distribution partners worldwide, indicating a distributor-led go-to-market for territories outside its direct-presence footprint.

Name

Lucane Pharma

Legal name

Eurocept International B.V.

Website

https://lucanepharma.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Lucane Pharma is a French pharmaceutical subsidiary of Eurocept Pharmaceuticals Holding that develops and commercializes reformulated medicines for rare disorders, serving patients with urea cycle disorders, leukemia, and multidrug-resistant tuberculosis across Europe, Turkey, and global distributor markets.

Ownership category

akta.pro rank

Product category

Orphan Disease Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Rare disease medicines
• Orphan drug development
• Specialty pharmaceuticals
• Pharmaceutical distribution
• Medicinal product commercialization

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: Lucane Pharma generates revenue through the sale of proprietary and licensed pharmaceutical products targeting rare diseases. Products are sold directly through their presence in France, Turkey, Spain, Italy, United Kingdom, and Benelux, as well as through distributors globally.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Lucane Pharma develops, registers, and commercializes proprietary and licensed pharmaceutical products targeting rare disorders (orphan drugs). Its marketed portfolio includes Xaluprine for acute lymphocytic leukemia, Ucedane for urea cycle disorders (carglumic acid), Pheburane (sodium phenylbutyrate) for urea cycle disorders in granules and oral solution forms, Granupas for multidrug-resistant tuberculosis, and Amsalyo (amsacrine). The company improves formulations of existing molecules, develops new presentations for specific age groups (neonates, children, adults), and sells directly to hospitals and pharmacies across France, Turkey, Spain, Italy, the UK, and Benelux while using distributors in other global markets.

Product overview

Lucane Pharma is a pharmaceutical company specializing in the development and commercialization of medicines for rare diseases. The company operates as part of Eurocept Pharmaceuticals Holding and offers a portfolio of niche medicines including Xaluprine (mercaptopurine oral suspension for acute lymphocytic leukemia), Ucedane (carglumic acid for urea cycle disorders), Pheburane (sodium phenylbutyrate for urea cycle disorders), Granupas (para-aminosalicylic acid for multidrug-resistant tuberculosis), and Amsalyo (amsacrine for infusion). Lucane Pharma improves formulations of existing products, develops new presentations fulfilling specific needs, and improves global accessibility of its products through direct presence in France, Turkey, Spain, Italy, United Kingdom, Benelux, and via distributors globally. The company is actively engaged in the development of 9 products for very rare disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Xaluprine Brand-name mercaptopurine oral suspension indicated for the treatment of acute lymphocytic leukemia. Belongs to the cytotoxics (chemotherapy) group that works by preventing cancer cells from multiplying, and was specifically designed to facilitate dosing in specific age groups.
• Ucedane An alternative version of carglumic acid with notable differences from the original, used in the treatment of urea cycle disorders (UCDs).
• Pheburane An alternative version of sodium phenylbutyrate with notable differences from the original, used in the treatment of urea cycle disorders (UCDs). Available in granules and oral solution forms.
• Granupas Brand-name para-aminosalicylic acid, a proven molecule used as part of an appropriate combination regimen for multidrug-resistant tuberculosis, which is rare in the EU today.
• Amsalyo Brand-name amsacrine powder for solution for infusion. Belongs to the cytotoxics (chemotherapy) group that works by preventing cancer cells from multiplying.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Recordati Rare Diseases: Specialty pharmaceutical division of Recordati focused on rare diseases with direct presence across Europe; directly comparable in commercial model, therapeutic focus (rare metabolic and endocrine disorders), and EMA-anchored portfolio strategy.
• BioMarin Pharmaceutical: Global rare-disease biotech with multiple EMA-approved products for very rare metabolic disorders; comparable in orphan-drug commercial focus and concentration on small-population specialty therapeutics.
• Swedish Orphan Biovitrum (Sobi): Public rare-disease specialty pharma headquartered in Europe, with a portfolio centered on niche metabolic, hematology, and immunology indications — directly comparable in orphan-drug strategy, EU regulatory focus, and reformulation/repositioning approach.
• Kyowa Kirin International: European specialty pharma arm of Kyowa Kirin focused on rare diseases and specialty therapeutics with strong EU commercialization; comparable in orphan-drug portfolio strategy and direct presence in multiple EU countries.
• Ultragenyx Pharmaceutical: Clinical-stage and commercial rare-disease biotech focused on metabolic and rare genetic disorders; comparable in orphan-drug regulatory pathway, small patient populations, and reformulation/repositioning of therapies.
• Jazz Pharmaceuticals: Specialty pharma with a portfolio spanning rare oncology, neurology, and sleep disorders; comparable in niche-indication focus, EMA presence, and reformulation of existing molecules (e.g., oral suspension presentations).
• Orphan Europe (Recordati Group): European rare-disease pharma (now part of Recordati) that develops and commercializes treatments for very rare disorders; highly comparable in mission, EMA orphan-drug portfolio, and small-population disease focus.

Broad incumbents

• Chiesi Farmaceutici: European-headquartered specialty pharma with rare-disease and neonatology franchises; comparable in EU direct commercialization, focus on underserved pediatric/rare populations, and reformulation of established molecules.
• Genzyme (Sanofi Rare Disease): Pioneering rare-disease franchise within Sanofi with deep expertise in metabolic disorders (e.g., enzyme replacement therapies); comparable in therapeutic area overlap (UCDs, metabolic conditions) but at global mega-cap scale.
• Alexion (AstraZeneca Rare Disease): Established global rare-disease franchise within AstraZeneca, with multiple EMA-approved orphan drugs and direct European commercialization — overlaps in therapeutic areas and regulatory pathways, but operates at vastly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lucanepharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucane Pharma